We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-12.67%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$14.7M
Cap. Flow
+$17.1M
Cap. Flow %
10.22%
Top 10 Hldgs %
63.99%
Holding
56
New
13
Increased
16
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
OSCR icon
Oscar Health
OSCR
+$9.25M
2
PRTA icon
Prothena Corp
PRTA
+$6.53M
3
CRL icon
Charles River Laboratories
CRL
+$6.01M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.93M
5
EHC icon
Encompass Health
EHC
+$5.87M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$7.14M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.53M
3
MTCR
Metacrine, Inc. Common Stock
MTCR
+$3.93M
4
MGTX icon
MeiraGTx Holdings
MGTX
+$3.84M
5
HUM icon
Humana
HUM
+$3.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.99%
2 Financials 1.14%
3 Industrials 0.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
51
Vertex Pharmaceuticals
VRTX
$121B
– –
-15,000
Closed -$2.72M
WAT icon
52
Waters Corp
WAT
$36.8B
– –
-4,000
Closed -$1.43M
ZBH icon
53
Zimmer Biomet
ZBH
$17.7B
– –
-13,390
Closed -$1.9M
ONCR
54
DELISTED
Oncorus, Inc.
ONCR
– –
-55,411
Closed -$518K
APTO
55
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-157
Closed -$154K
MTCR
56
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-1,145,034
Closed -$3.93M
1 2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q4 2021 Portfolio in Review

As of Q4 2021, Prosight Management held 56 positions worth $167M, down 8.1% from $182M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Prosight Management deployed $17.1M of net new capital in Q4 2021, opening 13 new positions and adding to 16 existing holdings. Its largest new stake was Charles River Laboratories: 15,481 shares worth $5.83M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 91% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Arena Pharmaceuticals Inc, an estimated $7.14M trimmed.

  • Prosight Management's largest Q4 2021 buy was Charles River Laboratories: 15,481 shares worth $5.83M.
  • Prosight Management added most to Oscar Health in Q4 2021, an estimated $9.25M increase.
  • Prosight Management's biggest Q4 2021 reduction was Arena Pharmaceuticals Inc, cutting an estimated $7.14M.
  • Prosight Management fully exited Metacrine, Inc. Common Stock in Q4 2021, selling an estimated $3.93M.
  • Prosight Management's ten largest holdings make up 64% of its $167M portfolio in Q4 2021.
  • Prosight Management opened 13 new positions and closed 20 in Q4 2021.
  • Prosight Management's portfolio value fell 8.1% quarter-over-quarter to $167M.

Based on Prosight Management's 13F filing for Q4 2021, filed 14 Feb 2022.